ATE535242T1 - Medizinische zusammensetzung zur prävention des übergangs zu einer operativen behandlung bei prostatahypertrophie - Google Patents

Medizinische zusammensetzung zur prävention des übergangs zu einer operativen behandlung bei prostatahypertrophie

Info

Publication number: ATE535242T1
Authority: AT; Austria
Prior art keywords: group; optionally substituted; transition; surgical treatment; medical composition
Prior art date: 2004-10-06

Application number

AT05790245T

Other languages

English (en)

Inventor

Yoshio Okubo

Tomoji Shimizu

Nobuhiko Arai

Yasuhiro Omori

Original Assignee

Kissei Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-10-06

Filing date

2005-10-04

Publication date

2011-12-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36142692&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE535242(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-10-04 Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical

2011-12-15 Application granted granted Critical

2011-12-15 Publication of ATE535242T1 publication Critical patent/ATE535242T1/de

Links

230000007704 transition Effects 0.000 title abstract 3
206010020880 Hypertrophy Diseases 0.000 title 1
210000002307 prostate Anatomy 0.000 title 1
238000001356 surgical procedure Methods 0.000 title 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 2
208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 2
125000002252 acyl group Chemical group 0.000 abstract 2
125000001931 aliphatic group Chemical group 0.000 abstract 2
125000000217 alkyl group Chemical group 0.000 abstract 2
230000002265 prevention Effects 0.000 abstract 2
238000002560 therapeutic procedure Methods 0.000 abstract 2
125000005041 acyloxyalkyl group Chemical group 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 1
125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
125000003387 indolinyl group Chemical class N1(CCC2=CC=CC=C12)* 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
125000005400 pyridylcarbonyl group Chemical group N1=C(C=CC=C1)C(=O)* 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Steroid Compounds (AREA)
Indole Compounds (AREA)

AT05790245T 2004-10-06 2005-10-04 Medizinische zusammensetzung zur prävention des übergangs zu einer operativen behandlung bei prostatahypertrophie ATE535242T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2004294358		2004-10-06
JP2005160843		2005-06-01
PCT/JP2005/018356 WO2006038619A1 (ja)	2004-10-06	2005-10-04	前立腺肥大症に対する手術療法への移行予防用医薬組成物

Publications (1)

Publication Number	Publication Date
ATE535242T1 true ATE535242T1 (de)	2011-12-15

Family

ID=36142692

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05790245T ATE535242T1 (de)	2004-10-06	2005-10-04	Medizinische zusammensetzung zur prävention des übergangs zu einer operativen behandlung bei prostatahypertrophie

Country Status (12)

Country	Link
US (1)	US20080090893A1 (de)
EP (1)	EP1806136B1 (de)
JP (1)	JPWO2006038619A1 (de)
KR (1)	KR20070059152A (de)
AT (1)	ATE535242T1 (de)
CA (1)	CA2582045C (de)
ES (1)	ES2378240T3 (de)
PL (1)	PL1806136T3 (de)
PT (1)	PT1806136E (de)
SI (1)	SI1806136T1 (de)
TW (1)	TWI377058B (de)
WO (1)	WO2006038619A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008106536A1 (en) *	2007-02-28	2008-09-04	Kissei Pharmaceuticals Co., Ltd.	Use of silodosin in a once daily administration for treating benign prostatic hyperplasia
CA2697137A1 (en) *	2007-07-20	2009-01-29	Astellas Pharma Inc.	Pharmaceutical composition for amelioration of lower urinary tract symptoms associated with prostatomegaly
EP2181707A1 (de) *	2008-11-04	2010-05-05	Astellas Ireland Co., Ltd.	Kombinierte Verwendung eines alpha-adrenergischen Rezeptorantagonisten und eines Antimuskarinmittels
WO2012000926A1 (de) *	2010-06-28	2012-01-05	Ratiopharm Gmbh	Silodosin-cyclodextrin einschlussverbindungen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999015202A1 (fr) *	1997-09-22	1999-04-01	Kissei Pharmaceutical Co., Ltd.	Medicaments contre la dysurie resultant d'une hypertrophie de la prostate
PT1293198E (pt) *	2001-09-14	2005-06-30	Kissei Pharmaceutical Co Lda	Dispositivo de administracao transdermica para o tratamento de patologias do tracto urinario
US20030225079A1 (en) *	2002-05-11	2003-12-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
UA78854C2 (en) *	2002-09-06	2007-04-25	Kissei Pharmaceutical	Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same
BRPI0404050A (pt) *	2003-09-24	2005-06-14	Bioxell Spa	Uso de um composto ou de um seu sal ou éster farmaceuticamente aceitável, formulação farmacêutica, formulação acondicionada, composto, e, método para prevenir e/ou tratar hiperplasia benigna da próstata em pacientes em necessidade de tal prevenção ou tratamento
US20070167511A1 (en) *	2004-03-05	2007-07-19	Kissei Pharmaceutical Co,. Ltd.	Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder

2005
- 2005-10-04 AT AT05790245T patent/ATE535242T1/de active
- 2005-10-04 KR KR1020077008738A patent/KR20070059152A/ko not_active Ceased
- 2005-10-04 EP EP05790245A patent/EP1806136B1/de not_active Expired - Lifetime
- 2005-10-04 ES ES05790245T patent/ES2378240T3/es not_active Expired - Lifetime
- 2005-10-04 CA CA2582045A patent/CA2582045C/en not_active Expired - Lifetime
- 2005-10-04 PT PT05790245T patent/PT1806136E/pt unknown
- 2005-10-04 PL PL05790245T patent/PL1806136T3/pl unknown
- 2005-10-04 SI SI200531474T patent/SI1806136T1/sl unknown
- 2005-10-04 JP JP2006539298A patent/JPWO2006038619A1/ja active Pending
- 2005-10-04 US US11/576,800 patent/US20080090893A1/en not_active Abandoned
- 2005-10-04 WO PCT/JP2005/018356 patent/WO2006038619A1/ja not_active Ceased
- 2005-10-06 TW TW094134936A patent/TWI377058B/zh not_active IP Right Cessation

Also Published As

Publication number	Publication date
TW200626143A (en)	2006-08-01
EP1806136A1 (de)	2007-07-11
CA2582045A1 (en)	2006-04-13
PL1806136T3 (pl)	2012-04-30
EP1806136A4 (de)	2008-03-12
US20080090893A1 (en)	2008-04-17
WO2006038619A1 (ja)	2006-04-13
PT1806136E (pt)	2012-03-08
KR20070059152A (ko)	2007-06-11
CA2582045C (en)	2013-10-22
SI1806136T1 (sl)	2012-03-30
ES2378240T3 (es)	2012-04-10
TWI377058B (en)	2012-11-21
JPWO2006038619A1 (ja)	2008-05-15
EP1806136B1 (de)	2011-11-30

Similar Documents

Publication	Publication Date	Title
MY141661A (en)	2010-05-31	17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
NO20060971L (no)	2006-05-02	Pyridazinderivater og deres anvendelse som terapeutiske midler
WO2001064639A3 (en)	2002-02-28	Pde iv inhibiting amides, compositions and pharmaceutical use
BG66087B1 (bg)	2011-03-31	Хинолинонови производни като тирозин киназни инхибитори
NO20071042L (no)	2007-04-19	5-substituerte 2-fenylaminobenzamider som MEK-inhibitorer
EA200400073A1 (ru)	2004-08-26	Пирролопиримидины как ингибиторы протеинкиназы
ATE443043T1 (de)	2009-10-15	Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
TR200201505T2 (tr)	2003-01-21	Terapötik maddeler olarak pirazolopirimidinler
IL173032A0 (en)	2006-06-11	Pyridazine derivatives and their use as therapeutic agents
AU2003301020A1 (en)	2004-07-22	Isoquinolinone derivatives and their use as therapeutic agents
NO20051527L (no)	2005-03-22	3-(sulfonamidoetyl) -indol-derivater for anvendelse som glukocorticoid-mimetica ved behandling av inflammatoriske, allergiske og proliferative sykdommer.
MY133473A (en)	2007-11-30	Haterocyclic glycyl beta-alanine derivatives.
PT1263730E (pt)	2008-02-11	Derivados amina para o tratamento de apoptose
AP2003002929A0 (en)	2003-12-31	Pyrrolopyrimidines as protein kinase inhibitors
NO975666D0 (no)	1997-12-05	Pyrroldovater og medisinsk sammensetning
MXPA04003611A (es)	2004-07-30	Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
DE60031686D1 (de)	2006-12-14	Pyrazinone, diese verbindungen enthaltende zusammenstellungen
HK1046404A1 (zh)	2003-01-10	用作nmda受体拮抗剂的取代的吡咯烷-2，3，4-三酮-3-肟衍生物
NO20052699L (no)	2005-06-06	4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
DE60034545D1 (de)	2007-06-06	Verwendung von chymase hemmern gegen vaskuläre lipidablagerung
SI1806136T1 (sl)	2012-03-30	Medicinski sestavek za preprečevanje prehoda na operativno zdravljenje prostatične hipertrofije
YU19302A (sh)	2004-11-25	4-benzilaminohinolin konjugovan žučnom kiselinom i njegovi heteroanalozi, postupak za njihovu proizvodnju, lekovi koji sadrže ta jedinjenja i njihova primena
ATE425756T1 (de)	2009-04-15	Verwendung von carbamazepinderivaten zur behandlung von agitatio in demenspatienten
ATE297926T1 (de)	2005-07-15	Hexahydropyrazino(1'2':1,6)-pyrido(3,4-b)indole 1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen
ATE465151T1 (de)	2010-05-15	4-aryloxy-chinolin-derivate als 5-ht6-modulatoren